Welcome to the Summit



Kenneth H. Mayer November 26th, 2012



Forum for Collaborative HIV Research



What a difference 2 years make

- iPrEX, other PrEP studies
- HPTN 052
- The "Cascade"
- ACA
- ECHPP
- Home HIV self-testing
- FDA approval of PrEP
- Presidential re-election
- USPHS & routine testing

The NEW ENGLAND JOURNAL of MEDICINE


ORIGINAL ARTICLE

Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men


Robert M. Grant, M.D., M.P.H., Javier R. Lama, M.D., M.P.H.,
Peter L. Anderson, Pharm.D., Vanessa McMahan, B.S., Albert V. Liu, M.D., M.P.H.,
Lorena Vargas, Pedro Goicochea, M.Sc., Martín Casapia, M.D., M.P.H.,
Juan Vicente Guanira-Carranza, M.D., M.P.H., Maria E. Ramirez-Cardich, M.D.,
Orlando Montoya-Herrera, M.Sc., Telmo Fernández, M.D.,
Valdilea G. Veloso, M.D., Ph.D., Susan P. Buchbinder, M.D.,
Suwat Chariyalertsak, M.D., Dr.P.H., Mauro Schechter, M.D., Ph.D.,
Linda-Gail Bekker, M.B., Ch.B., Ph.D., Kenneth H. Mayer, M.D.,
Esper Georges Kallás, M.D., Ph.D., K. Rivet Amico, Ph.D., Kathleen Mulligan, Ph.D.,
Lane R. Bushman, B.Chem., Robert J. Hance, A.A., Carmela Ganoza, M.D.,
Patricia Defechereux, Ph.D., Brian Postle, B.S., Furong Wang, M.D.,
J. Jeff McConnell, M.A., Jia-Hua Zheng, Ph.D., Jeanny Lee, B.S.,
James F. Rooney, M.D., Howard S. Jaffe, M.D., Ana I. Martinez, R.Ph.,
David N. Burns, M.D., M.P.H., and David V. Glidden Ph.D., for the iPrEx Study Team*



Clinical Trial Evidence that Antiretroviral Drugs Prevent HIV Transmission



HPTN 052: HIV Transmission by HAART but many were not monogamous



PrEP (Like ART) Works When Taken

	Blood Samples With Tenofovir Detected, %	HIV Protection Efficacy in Randomized Comparison,%
Partners PrEP*[1]	81	75
TDF2 ^[2]	79	62
iPrEx ^[3]	51	44
FEM-PrEP ^[4]	26	6


^{*}TDF/FTC arm

There is a clear dose-response between evidence of PrEP use and efficacy


1. Baeten JM, et al. N Engl J Med. 2012; [Epub ahead of print]. 2. Thigpen MC, et al N Engl J Med. 2012; [Epub ahead of print]. 3. Grant RM, et al. N Engl J Med. 2010; 363:2587-2599. 4. Van Damme L, et al N Engl J Med. 2012; [Epub ahead of print].

CDC: HIV-Infected Persons Engaged in Selected Stages of the Continuum of Care (2009)

CDC and Prevention National HIV Surveillance System



n=1,148,200 HIV-infected persons, 18% of whom are unaware of their infection. Hall HI, et al. 19th IAC. Washington, DC, 2012. Abstract FrLBX05.








HIV incidence in Black MSM (HPTN 061)

- HIV incidence was high: 2.8%; 95% CI: 1.8,4.1
 - Young men, 18-30: 5.9% (95% CI: 3.6, 9.1)
 - Those reporting URA: 4.9% (95% CI: 3.0, 7.4)
 - Gay/homosexual and those with male partners only: 4.3% (95% CI: 2.6, 6.7)
 - Those with STIs: 6.0% (95% CI: 2.4, 12.5)
- Targeted, tailored and culturally appropriate combination HIV prevention strategies (behavioral, social, structural and biomedical) are urgently needed.

Trends in HIV Infection and Death among People Reported with HIV/AIDS by Year: Massachusetts, 2000–2011



Note: 2011 Death data are preliminary

Data Source: MDPH HIV/AIDS Surveillance Program; Data as of 9/1/12

What we need to know

- How to best expand testing, linkage and retention in care
- How to roll out self-testing to ensure increased serostatus knowledge
- The role of PrEP as part of a prevention package
- Which behavioral interventions improve medication adherence, decrease risk taking
- How ACA implementation will affect AIDS care, including Ryan-White reauthorization